多西紫杉醇联合卡铂治疗老年人晚期非小细胞肺癌的近期疗效

目的:观察多西紫杉醇联合卡铂治疗老年人晚期非小细胞肺癌(NSCLC)的近期疗效,评价其安全性。方法:老年晚期NSCLC共58例,ECOG体能状况评分均≤2。多西紫杉醇75mg/m2,d1;卡铂AUC=5,d1。每3周为一个周期,共治疗2～4个周期。每治疗2个周期后复查CT,评价疗效。生存率分析采用Kaplan-Meier模型及Log-rank检验。结果:全组58例中,CR1例、PR22例、SD26例、PD9例,有效率39.7%(23/58)。随访时间为4～18个月,随访率94.8%(55/58)。中位生存期为11.0个月,中位疾病进展时间为6.4个月,一年生存率为51.7%(30/58)。毒性反应主要为骨髓抑制、脱发和恶心呕吐,III-IV度白细胞减少发生率为53.4%(31/58)。结论:多西紫杉醇联合卡铂治疗老年人晚期NSCLC疗效好,毒性反应可耐受;对于体能状况好的老年晚期NSCLC患者可考虑作为一线化疗方案。

Clinical Observation of Chemotherapy with Docetaxel/Carboplatin for Elderly Advanced Non-Small Cell Lung Cancer

Objective:To observe the efficacy and safety of docetaxel combined with carboplatin in the treatment of elderly advanced non-small cell lung cancer(NSCLC).Methods:A total of fifty-eight patients with elderly NSCLC were enrolled in the study.The patients were given docetaxel 75mg /m2 on day 1,and carboplatin(AUC=5) on day 1,and it was repeated at d21.The patients recieved 2 to 4 treatment cycles.Results:Out of 58 patients,1 achieved complete response,22 achieved partial response,26 had stable disease,and 9 were progressive.The overall response rate was 39.7%.The median overall survival time was 11.0 months.The estimated median time to tumor progression was 6.4 months,and the 1-year survival rate was 51.7%.The main toxicity included myelosuppression,alopecia,nausea and vomiting.53.4% of patients had grade 3/4 hematologic toxicities.Conclusion:Docetaxel combined with carboplatin is effective in the treatment of elderly advanced NSCLC and its toxic reactions are slight and tolerable.